Lisbeth Bjerring Jensen

TL;DR: This study shows NN2211 has a pharmacokinetic profile supporting a daily dose in human beings, but also that subjects treated with NN 2211 rather than placebo, had a higher incidence of adverse events, most notably dizziness and adverse events related to the gastrointestinal system.

TL;DR: Evidence is provided that NN2211 has a pharmacokinetic profile consistent with once-daily dosing in humans, and there was a higher incidence of adverse events after active treatment compared with placebo treatment.

TL;DR: Treatment with IAsp is associated with an increase in cross-reactive insulin antibodies, with a subsequent fall toward baseline values, without any indication of clinical relevance, and there was no consistent relationship between antibody formation and glycemic control or between antibodies formation and safety in terms of adverse events.

TL;DR: The details of a novel reiterated stepwise equilibrium dialysis assay that has successfully been used to quantify liraglutide plasma protein binding are reported, which could have an application in the quantification of plasmaprotein binding of other highly lipophilic drug molecules.

TL;DR: The insulin aspart-specific enzyme-linked immunosorbent assay described in this study is well suited to study the bioavailability, bioequivalence, and pharmacokinetics of this insulin analogue.